Read by QxMD icon Read

HBsAg Clearance

Zhongliang Shen, Yuliang Rao, Shuai Tao, Mengjun Luo, Lijun Ming, Jing Liu, Shaokun Pan, Youhua Xie
Global adoption of hepatitis B virus (HBV) vaccines has greatly reduced new HBV infections. Current HBV vaccines are liquid suspensions containing recombinant hepatitis B surface antigen (HBsAg) particles mixed with aluminum phosphate or aluminum hydroxide. Refrigeration (2-8°C) as recommended for vaccine transport and storage may be unachievable in certain HBV-prevalent developing countries or regions. In this study, we stored yeast-expressed HBsAg and aluminum hydroxide separately at the standard (4°C) and elevated temperature (25, 37, or 45°C) for 14, 23, and 30 days, then mixed them and used the mixture to vaccinate mice with a prime-boost program...
November 8, 2016: Acta Biochimica et Biophysica Sinica
H Ito, T Ando, M Nakamura, H Ishida, A Kanbe, K Kobiyama, T Yamamoto, K J Ishii, A Hara, M Seishima, T Ishikawa
A persistent hepatitis B virus (HBV) infection is characterized by a lack of or a weak immune response to HBV, which may be reflective of tolerance to HBV. Efficient induction of HBV-specific immune response leads to the clearance of HBV in patients with a chronic HBV infection. CpG oligodeoxynucleotides (ODN) has a powerful adjuvant effect in HBV vaccination. A recent report demonstrated that the immunization by B/K CpG ODN (K3) wrapped by the nonagonistic Dectin-1 ligand, schizophyllan (SPG), namely K3-SPG, was more effective in the induction of antigen-specific immune response than that by K3...
November 3, 2016: Journal of Viral Hepatitis
Yasuyuki Hara, Kazuaki Tokodai, Chikashi Nakanishi, Shigehito Miyagi, Naoki Kawagishi
BACKGROUND: Hepatitis B core antibody (HBcAb)-positive graft is reported to cause de novo hepatitis B after liver transplantation with a probability of 38-100 % without prophylaxis. Hepatitis B surface antigen loss is reported to be achieved with a probability of only 3-8 % in the patients treated by antiviral agents. We present an extremely rare case of spontaneous resolution of de novo hepatitis B after living donor liver transplantation (LDLT) with HBcAb-positive graft. CASE PRESENTATION: An 8-year-old female patient underwent LDLT for end-stage biliary atresia using an HBcAb-positive left lobe graft...
December 2016: Surgical Case Reports
Vijay K Karra, Soumya J Chowdhury, Rajesh Ruttala, Sunil K Polipalli, Premashis Kar
BACKGROUND/OBJECTIVE: Quantification of serum hepatitis B antigen (HBsAg) is an important test that marks active infection with hepatitis B and helps in the prediction of the clinical outcome and management of hepatitis B virus (HBV) infection. Correlation with HBV DNA quantitative levels may help in developing strategies for antiviral treatment. This study is aimed to evaluate HBsAg titres in various phase of HBV infection in HBsAg positive patients, and its correlation with HBV DNA viral load levels...
September 2016: Journal of Clinical and Experimental Hepatology
Slim Fourati, Jean-Michel Pawlotsky
Hepatitis B virus (HBV) infects approximately 240 million individuals worldwide. Recent advances in the virology, immunopathogenesis, and diagnosis of HBV infection are summarized in this review article. The identification of a hepatocyte-specific cellular receptor for HBV, the sodium taurocholate co-transporting polypeptide (NTCP), made it possible to develop reliable cell culture systems and better understand the early steps of the viral lifecycle. Viral and host factors involved in covalently closed circular DNA synthesis, stability, and transcriptional regulation have also been identified and provide potential targets for new drugs...
2016: F1000Research
Yuka Ochi, Senju Hashimoto, Naoto Kawabe, Michihito Murao, Takuji Nakano, Toshiki Kan, Kazunori Nakaoka, Masashi Ohki, Takamitsu Kurashita, Tomoki Takamura, Sayuri Nomura, Toru Nishikawa, Aiko Fukui, Keisuke Osakabe, Naohiro Ichino, Kentaro Yoshioka
AIM: Genome-wide association studies have revealed that single nucleotide polymorphism (SNP) of human leukocyte antigen (HLA)-DQ is associated with the clearance of hepatitis B surface antigen (HBsAg) in acute hepatitis B virus (HBV) infection. We examined the effects of SNPs on the development of hepatocellular carcinoma (HCC) and markers of HBV in chronic HBV infection. METHODS: The SNPs of HLA-DQ (rs2856718 and rs7453920) were determined in 299 patients with chronic HBV infection...
August 31, 2016: Hepatology Research: the Official Journal of the Japan Society of Hepatology
Markus Cornberg, Vincent Wai-Sun Wong, Stephen Locarnini, Maurizia Brunetto, Harry L A Janssen, Henry Lik-Yuen Chan
In the past 10 years, there are a lot of enthusiasms on the use of serum hepatitis B surface antigen (HBsAg) quantification to predict disease activity and monitor treatment response in chronic hepatitis B. The measurement of HBsAg level has been standardized in IU/mL and nowadays it is almost mandatory with the development of new antiviral treatments as HBsAg seroclearance, i.e. functional cure of hepatitis B, is now considered the goal of therapy. Recently, improved understanding on molecular virology of HBsAg, particularly on the relative roles of covalently closed circular DNA and integrated HBV DNA, has shed new lights on the interpretation of HBsAg level in different phases of chronic hepatitis B...
August 26, 2016: Journal of Hepatology
M Viganò, F Invernizzi, G Grossi, P Lampertico
BACKGROUND: A short-term course of pegylated-interferon (Peg-IFN), or a long-term treatment with a third generation nucleot(s)ide analogue (NUC), of chronic hepatitis B (CHB) infection achieves viral suppression and may prevent disease progression. Owing to different mechanisms of action of the two regimens, a Peg-IFN and NUC combination treatment may be an attractive approach to enhance the off-treatment rates of virological and serological response. AIM: To review the literature on combinations of Peg-IFN plus NUC, including the simultaneous initiation of Peg-IFN and NUC in naïve patients; an 'add-on' combination, where Peg-IFN is started at variable times after the beginning of NUC; or a 'switch-to' strategy usually from NUC to Peg-IFN...
October 2016: Alimentary Pharmacology & Therapeutics
Alpay Ari, Şebnem Çalik, Selma Tosun, Sibel Özsu Yilmaz
BACKGROUND/AIM: The incidence and predictors of spontaneous hepatitis B surface-antigen (HBsAg) seroclearance in patients with chronic hepatitis B virus (HBV) were evaluated. MATERIALS AND METHODS: A total of 1427 patients with chronic HBV infection, who were followed between 1994 and 2013, were investigated in this retrospective study. All data were extracted from patient files. RESULTS: Spontaneous HBsAg seroclearance occurred in 84 patients during 8798 person-years of follow-up...
2016: Turkish Journal of Medical Sciences
S S Zhu, Y Dong, L M Wang, Z Q Xu, D W Chen, Y Gan, F C Wang, J G Yan, L L Cao, P Wang, M Zhang, H F Zhang
OBJECTIVE: To investigate the liver pathological characteristics and the clearance rate of hepatitis B surface antigen (HBsAg) with antiviral treatment for 1 to 7 years old children with heptitis B e antigen(HBeAg)-negative chronic hepatitis B. METHOD: A total of 49 cases with HBeAg-negative chronic hepatitis B were treated with interferon (IFN) or IFN treatment for 6 months added with lamivudine, and were followed up for at least 6 months.Retrospective analysis was performed on the liver pathological characteristics, the efficacy of antivirus treatment and its influencing factors of the HBsAg clearance rate in the cases from June 2006 to December 2013 in the 302 Hospital of People's Liberation Army...
August 2016: Zhonghua Er Ke za Zhi. Chinese Journal of Pediatrics
Saleh Shahbazi Azar, Maryam Mansoori, Marzieh Attar, Majid Shahbazi
BACKGROUND: Hepatitis B virus (HBV) is a key factor for hepatocellular carcinoma (HCC). About 350 million people are affected by chronic infection which is related to the rapid development of liver diseases as well as hepatitis, cirrhosis and hepatocellular carcinoma. Expression of tumor necrosis factor alpha (TNFα) in the liver demonstrates a major genetic polymorphism which is involved in resistance or susceptibility to chronic HBV infection. MATERIALS AND METHODS: In this study, two populations were studied by the sequence specific primerpolymerase chain reaction (SSPPCR) method: HBV cases (n=409), who were HBSAg+, and healthy controls (n=483)...
2016: Asian Pacific Journal of Cancer Prevention: APJCP
Gonzague Jourdain, Nicole Ngo-Giang-Huong, Tim R Cressey, Lei Hua, Linda Harrison, Camlin Tierney, Nicolas Salvadori, Luc Decker, Patrinee Traisathit, Wasna Sirirungsi, Woottichai Khamduang, Chureeratana Bowonwatanuwong, Thanyawee Puthanakit, George K Siberry, Diane Heather Watts, Trudy V Murphy, Jullapong Achalapong, Suchat Hongsiriwon, Virat Klinbuayaem, Satawat Thongsawat, Raymond T Chung, Stanislas Pol, Nantasak Chotivanich
BACKGROUND: Chronic hepatitis B virus (HBV) infection is complicated by cirrhosis and liver cancer. In Thailand, 6-7 % of adults are chronically infected with HBV. The risk of mother-to-child transmission (MTCT) of HBV has been estimated to be about 12 % when mothers have a high hepatitis B viral load, even if infants receive passive-active prophylaxis with HBV immunoglobulin (HBIg) and initiate the hepatitis B vaccine series at birth. We designed a study to assess the efficacy and safety of a short course of maternal tenofovir disoproxil fumarate (TDF) among women with a marker of high viral load for the prevention of MTCT of HBV...
August 9, 2016: BMC Infectious Diseases
A Boyd, L Piroth, S Maylin, M Maynard-Muet, F Lebossé, C Bouix, C Lascoux-Combe, N Mahjoub, P-M Girard, C Delaugerre, F Carrat, K Lacombe, P Miailhes
In hepatitis B "e" antigen (HBeAg) positive patients with hepatitis B virus (HBV) mono-infection, intensification of nucleos(t)ide analogue treatment with pegylated interferon (PegIFN) could help induce higher HBeAg seroclearance rates. Our aim was to determine the long-term effect of adding PegIFN to tenofovir (TDF)-containing antiretroviral therapy on seroclearance in HBeAg-positive patients co-infected with the human immunodeficiency virus (HIV) and HBV. In this prospective matched cohort study, 46 patients with 1-year PegIFN intensification during TDF-containing antiretroviral therapy (TDF+PegIFN) were matched 1:1 to controls undergoing TDF without PegIFN (TDF) using a time-dependent propensity score based on age, CD4+ count and liver cirrhosis status...
August 3, 2016: Journal of Viral Hepatitis
K L Cheng, M M Xu, Q Qiu, Y Li, L K Yang, X W Duan, Y Chen, Z P Duan, L Wang
OBJECTIVE: To investigate HBsAg clearance rate in previously untreated patients with HBeAg-positive chronic hepatitis B (CHB) treated with nucleos(t)ides and interferons and its influencing factors based on the clinical diagnosis and treatment dat. METHODS: A retrospective cohort study was conducted in 1 767 previously untreated HBeAg-positive CHB patients who visited Beijing You'an Hospital from February 14, 2008 to December 31, 2012. HBsAg clearance rates were calculated for patients with different characteristics, and the Cox regression model was used to investigate the influencing factors for HBsAg clearance...
May 20, 2016: Zhonghua Gan Zang Bing za Zhi, Zhonghua Ganzangbing Zazhi, Chinese Journal of Hepatology
X H Yang, X F Shi
Serum hepatitis B surface antigen (HBsAg) quantification can reflect the level of HBV replication and can be used as a surrogate maker for the evaluation of infected cells. Recent studies have shown that HBsAg quantification can help to distinguish the nature history of chronic hepatitis B and predict spontaneous clearance of HBsAg and the risk of progressive liver diseases. The dynamic change in HBsAg helps to predict the therapeutic effects of interferon and nucleoside analogues and sustained virologic response, guide withdrawal, and improve and optimize the therapeutic strategy for chronic hepatitis B in clinical practice...
April 2016: Zhonghua Gan Zang Bing za Zhi, Zhonghua Ganzangbing Zazhi, Chinese Journal of Hepatology
X D Luo, X P Chen, R Chen, X F Chen, J Huang
OBJECTIVE: To investigate the efficacy and safety of 104-week sequential therapy with telbivudine or entecavir in HBeAg-positive chronic hepatitis B (CHB) patients with suboptimal responses to 24-week pegylated interferon-α-2a (PEG-IFN-α-2a) therapy. METHODS: A total of 130 HBeAg-positive CHB patients with HBV DNA≥5.0 lg IU/ml and a reduction in HBsAg quantitation < 1 lg IU/ml compared with baseline who received PEG-IFN-α-2a therapy for 24 weeks were enrolled and randomly divided into telbivudine group and entecavir group, and 5 of them were lost...
April 2016: Zhonghua Gan Zang Bing za Zhi, Zhonghua Ganzangbing Zazhi, Chinese Journal of Hepatology
Massimo Levrero, Barbara Testoni, Fabien Zoulim
Current HBV treatments control replication and liver disease progression in the vast majority of treated patients. However, HBV patients often require lifelong therapies due to the persistence of transcriptionally active viral cccDNA mini-chromosome in the nucleus, which is not directly targeted by current antiviral therapies. A true complete cure of HBV would require clearance of intranuclear cccDNA from all infected hepatocytes. An intermediate but still relevant step forward that would allow treatment cessation would be reaching a functional cure, equivalent to resolved acute infection, with a durable HBsAg loss±anti-HBs seroconversion, undetectable serum DNA and persistence of cccDNA in a transcriptionally inactive status...
June 2016: Current Opinion in Virology
G A Niro, A Smedile, R Fontana, A Olivero, A Ciancio, M R Valvano, F Pittaluga, N Coppola, H Wedemeyer, K Zachou, A Marrone, M Fasano, G Lotti, P Andreone, A Iacobellis, A Andriulli, M Rizzetto
BACKGROUND: Therapy of chronic hepatitis D with Interferon is successful when testing for HDV-RNA turns negative. This end-point is disputed. AIM: To assess the role of serum hepatitis B surface antigen (HBsAg) in the clearance of HDV-RNA in pegylated interferon (Peg-IFN)-treated chronic hepatitis D (CHD). METHODS: Sixty-two patients with CHD, treated with Peg-IFN, were considered. The patients belonged to three groups: 14 patients cleared the HBsAg and HDV-RNA (responders, R), 12 cleared the HDV-RNA remaining positive for HBsAg (partial responders, PR) and 36 cleared neither the HBsAg nor the HDV-RNA (nonresponders, NR)...
September 2016: Alimentary Pharmacology & Therapeutics
Forough Golsaz-Shirazi, Hamed Mohammadi, Mohammad Mehdi Amiri, Jalal Khoshnoodi, Gholam Ali Kardar, Mahmood Jeddi-Tehrani, Fazel Shokri
The common "a" determinant is the major immunodominant region of hepatitis B surface antigen (HBsAg) shared by all serotypes and genotypes of hepatitis B virus (HBV). Antibodies against this region are thought to confer protection against HBV and are essential for viral clearance. Mutations within the "a" determinant may lead to conformational changes in this region, which can affect the binding of neutralizing antibodies. There is an increasing concern about identification and control of mutant viruses which is possible by comprehensive structural investigation of the epitopes located within this region...
October 2016: Archives of Virology
Teerha Piratvisuth, Piyawat Komolmit, Henry Ly Chan, Tawesak Tanwandee, Wattana Sukeepaisarnjaroen, Mário G Pessoa, Eduardo Fassio, Suzane K Ono, Fernando Bessone, Jorge Daruich, Stefan Zeuzem, Michael Manns, Alkaz Uddin, Yuhong Dong, Aldo Trylesinski
BACKGROUND: A 2-year roadmap study was conducted to evaluate the efficacy and safety of tenofovir intensification at Week 24 in patients with chronic hepatitis B (CHB) receiving telbivudine. SCOPE: A prospective multicenter study was conducted in treatment-naive patients with hepatitis B e antigen (HBeAg)-positive CHB. All patients received telbivudine (600 mg/day) until Week 24. Thereafter, patients with detectable hepatitis B virus (HBV) DNA (≥300 copies/mL) were administered tenofovir (300 mg/day) plus telbivudine, and patients with undetectable HBV DNA continued telbivudine monotherapy until Week 104...
2016: Drugs in Context
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"